Comparing the quality of life of neuropathic patients treated with gabapentin and pregabalin at the neuropathic poly of the NTB provincial hospital in 2019

Nurul, Qiyaam (2021) Comparing the quality of life of neuropathic patients treated with gabapentin and pregabalin at the neuropathic poly of the NTB provincial hospital in 2019. Pharmacy Education. pp. 56-64. ISSN 1477-2701

[img] Text (Article)
BMJ_NuQi.pdf

Download (897kB)
[img] Text (SIMILARITY CHECK)
1438+Qiyaam_v3.pdf.pdf

Download (360kB)
[img] Text ((Bukti Korespondensi Jurnal))
Koresponden_Comparing the Quality of Life of Neuropathic Patients Treated with Gabapentin.pdf

Download (598kB)

Abstract

Neuropathic pain is caused by the malfunctioning of the central nervous system or the peripheral nervous system. This pain is chronic and so it disrupts a patient’s quality of life which can lead to them becoming frustrated. Aim: The purpose of this study was to compare the quality of life of neuropathic patients using either gabapentin or pregabalin at the neuropathic clinic of the Regional General Hospital of West Nusa Tenggara Province in 2019. Methods: This study used a cross-sectional study design. The sampling technique that was used was purposive sampling which was carried out by filling out the EQ-5D-3L and EQ-VAS questionnaires. Results: The results showed no significant difference between the quality of life of the patients using gabapentin and the patients using pregabalin as the EQ-5D-3L questionnaire had a value of p = 0.683. There was no significant difference between the quality of life between the gabapentin and pregabalin groups using the EQ-VAS questionnaire which had a value of p = 1.000.

Item Type: Article
Subjects: 600 Teknologi dan Ilmu Terapan > 615 Farmakologi dan Terapi Farmakologi > 615.4 Farmasi Praktis
Divisions: Kepegawaian UMMAT > Angka Kredit Dosen
Depositing User: NANI SULISTIANINGSIH
Date Deposited: 17 Oct 2022 08:19
Last Modified: 14 Dec 2022 08:45
URI: http://repository.ummat.ac.id/id/eprint/6227

Actions (login required)

View Item View Item